![Upendra K. Marathi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Upendra K. Marathi
Amministratore Delegato presso 7 Hills Pharma LLC
Posizioni attive di Upendra K. Marathi
Società | Posizione | Inizio | Fine |
---|---|---|---|
7 Hills Pharma LLC
![]() 7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Amministratore Delegato | - | - |
Fondatore | - | - | |
Presidente | - | - |
Storia della carriera di Upendra K. Marathi
Precedenti posizioni note di Upendra K. Marathi
Società | Posizione | Inizio | Fine |
---|---|---|---|
BCM Technologies, Inc.
![]() BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Corporate Officer/Principal | - | - |
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Corporate Officer/Principal | - | - |
Rice University | Corporate Officer/Principal | - | - |
MediGen Group LLC
![]() MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Investitore di Private Equity | - | - |
Formazione di Upendra K. Marathi
Rice University | Masters Business Admin |
Loyola University of Chicago | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 3 |
Finance | 3 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
PLx Pharma, Inc. /Old/
![]() PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
BCM Technologies, Inc.
![]() BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Finance |
MediGen Group LLC
![]() MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Finance |
7 Hills Pharma LLC
![]() 7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Health Technology |
- Borsa valori
- Insiders
- Upendra K. Marathi
- Esperienza